pCI-neo-mOVA Citations (14)
Originally described in: Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.Yang J, Sanderson NS, Wawrowsky K, Puntel M, Castro MG, Lowenstein PR Proc Natl Acad Sci U S A. 2010 Mar 9. 107(10):4716-21. PubMed Journal
Articles Citing pCI-neo-mOVA
Articles |
---|
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, Lyssiotis C, Liu JR, Kryczek I, Zou W. Nat Immunol. 2017 Dec;18(12):1332-1341. doi: 10.1038/ni.3868. Epub 2017 Oct 30. PubMed |
Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation. Theisen DJ, Ferris ST, Briseno CG, Kretzer N, Iwata A, Murphy KM, Murphy TL. Cancer Immunol Res. 2019 Jan;7(1):29-39. doi: 10.1158/2326-6066.CIR-18-0138. Epub 2018 Nov 27. PubMed |
CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. Nature. 2019 May;569(7755):270-274. doi: 10.1038/s41586-019-1170-y. Epub 2019 May 1. PubMed |
Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells. Ou P, Wen L, Liu X, Huang J, Huang X, Su C, Wang L, Ni H, Reizis B, Yang CY. J Exp Med. 2019 Sep 2;216(9):2091-2112. doi: 10.1084/jem.20190041. Epub 2019 Jul 1. PubMed |
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+) T Cells. Etxeberria I, Bolanos E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sanchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, Ochoa MC, Labiano S, Garasa S, Rodriguez I, Vidal A, Mancheno U, Hervas-Stubbs S, Azpilikueta A, Otano I, Aznar MA, Sanmamed MF, Inoges S, Berraondo P, Teijeira A, Melero I. Cancer Cell. 2019 Dec 9;36(6):613-629.e7. doi: 10.1016/j.ccell.2019.10.006. Epub 2019 Nov 21. PubMed |
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, Hock AK, Walton JB, Morton JP, Gronroos E, Mason S, Yang M, McNeish I, Swanton C, Blyth K, Vousden KH. Cell Rep. 2020 Jan 14;30(2):481-496.e6. doi: 10.1016/j.celrep.2019.12.028. PubMed |
Cellular cytotoxicity is a form of immunogenic cell death. Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I, Etxeberrria I, Bolanos E, Azpilikueta A, Garasa S, Casares N, Luis Perez Gracia J, Rodriguez-Ruiz ME, Berraondo P, Melero I. J Immunother Cancer. 2020 Mar;8(1). pii: jitc-2019-000325. doi: 10.1136/jitc-2019-000325. PubMed |
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseno CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM. Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12. PubMed |
Lung megakaryocytes are immune modulatory cells. Pariser DN, Hilt ZT, Ture SK, Blick-Nitko SK, Looney MR, Cleary SJ, Roman-Pagan E, Saunders J 2nd, Georas SN, Veazey J, Madere F, Santos LT, Arne A, Huynh NP, Livada AC, Guerrero-Martin SM, Lyons C, Metcalf-Pate KA, McGrath KE, Palis J, Morrell CN. J Clin Invest. 2021 Jan 4;131(1). pii: 137377. doi: 10.1172/JCI137377. PubMed |
Protective and Therapeutic Effects of an IL-15:IL-15Ralpha-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System. Do-Thi VA, Lee H, Jeong HJ, Lee JO, Kim YS. Cancers (Basel). 2021 Aug 11;13(16). pii: cancers13164039. doi: 10.3390/cancers13164039. PubMed |
CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L. J Immunother Cancer. 2022 May;10(5). pii: jitc-2021-004022. doi: 10.1136/jitc-2021-004022. PubMed |
Dual near-infrared II laser modulates the cellular redox state of T cells and augments the efficacy of cancer immunotherapy. Katagiri W, Yokomizo S, Ishizuka T, Yamashita K, Kopp T, Roessing M, Sato A, Iwasaki T, Sato H, Fukuda T, Monaco H, Manganiello S, Nomura S, Ng MR, Feil S, Ogawa E, Fukumura D, Atochin DN, Choi HS, Kashiwagi S. FASEB J. 2022 Oct;36(10):e22521. doi: 10.1096/fj.202200033R. PubMed |
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. Zhang L, Jiang L, Yu L, Li Q, Tian X, He J, Zeng L, Yang Y, Wang C, Wei Y, Jiang X, Li J, Ge X, Gu Q, Li J, Wu D, Sadler AJ, Yu D, Xu D, Gao Y, Yuan X, He B. Nat Commun. 2022 Sep 15;13(1):5413. doi: 10.1038/s41467-022-33116-z. PubMed |
PIKfyve controls dendritic cell function and tumor immunity. Choi JE, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, Gondal M, Tien JC, Maj T, Yazdani S, Parolia A, Xia H, Zhou J, Wei S, Grove S, Vatan L, Lin H, Li G, Zheng Y, Zhang Y, Cao X, Su F, Wang R, He T, Cieslik M, Green MD, Zou W, Chinnaiyan AM. bioRxiv [Preprint]. 2024 Jul 1:2024.02.28.582543. doi: 10.1101/2024.02.28.582543. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.